

- Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). *J Clin Endocrinol Metab* 2012;97:2990–3001.
- Ito T, Igarashi H, Uehara H, et al. Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. *Medicine* 2013;92:135–181.
- Wells SA Jr, Pacini F, Robinson BC, et al. Multiple endocrine neoplasia Type 2 and familial medullary thyroid carcinoma: an update. *J Clin Endocrinol Metab* 2013;98:3149–3164.
- Fox E, Widemann BC, Chuk MK, et al. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. *Clin Cancer Res* 2013;19:4239–4248.
- Lee M, Pellegata NS. Multiple endocrine neoplasia syndromes associated with mutation of p27. *J Endocrinol Invest* 2013;36:781–787.
- Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). *Mol Cell Endocrinol* 2014;386:2–15.
- Romei C, Pardi E, Cetani F, et al. Genetic and clinical features of multiple endocrine neoplasia type 1 and 2. *J Oncol* 2012;1–15.
- Brandi M, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. *J Clin Endocrinol Metab* 2001;86:5658–6571.
- Norton JA, Cornelius MJ, Doppman JL, et al. Effect of parathyroidectomy in patients with hyperparathyroidism and Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1: a prospective study. *Surgery* 1987;102:958–966.
- Singh MH, Fraker DL, Metz DC. Importance of surveillance for multiple endocrine neoplasia-1 and surgery in patients with sporadic Zollinger-Ellison syndrome. *Clin Gastroenterol Hepatol* 2012;10:1262–1269.
- Lopez CL, Falconi M, Waldmann J, et al. Partial pancreaticoduodenectomy can provide cure for duodenal gastrinoma associated with multiple endocrine neoplasia type 1. *Ann Surg* 2013;257:308–314.
- Norton JA, Fang TD, Jensen RT. Surgery for gastrinoma and insulinoma in multiple endocrine neoplasia type 1. *J Natl Compr Canc Netw* 2006;4:148–153.
- Weber HC, Venzon DJ, Lin JT, et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. *Gastroenterology* 1995;108:1637–1649.
- Skogseid B, Oberg K, Eriksson B, et al. Surgery for asymptomatic pancreatic lesions in multiple endocrine neoplasia type 1. *World J Surg* 1996;20:872–877.
- Norton JA, Melcher ML, Gibril F, et al. Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. *Surgery* 2004;136:1267–1274.
- Simonds WF, Varghese S, Marx SJ, et al. Cushing's syndrome in multiple endocrine neoplasia type 1. *Clin Endocrinol* 2012;76:379–386.
- Yao JC, Eisner MP, Leary C, et al. Population-based study of islet cell carcinoma. *Ann Surg Oncol* 2007;14:3492–3500.
- Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. *N Engl J Med* 2011;363:514–523.
- Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. *N Engl J Med* 2011;364:501–513.
- Froeling V, Elgeti F, Maurer MH, et al. Impact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia. *Ann Nucl Med* 2012;26:738–743.
- Schulte KM, Machens A, Fugazzola L, et al. The clinical spectrum of multiple endocrine neoplasia type 2a caused by the rare intracellular RET mutation S891A. *J Clin Endocrinol Metab* 2010;95:E92–E97.
- Scholten A, Valk GD, Ulfman D, et al. Unilateral adrenalectomy for pheochromocytoma in multiple endocrine neoplasia type 2 patients. *Ann Surg* 2011;254:1022–1027.
- Thosani S, Ayala-Ramirez M, Palmer L, et al. The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2. *J Clin Endocrinol Metab* 2013;98:E1813–E1819.
- Machens A, Lorenz K, Dralle H. Peak incidence of pheochromocytoma and primary hyperparathyroidism in multiple endocrine neoplasia 2: need for age-adjusted biochemical screening. *J Clin Endocrinol Metab* 2013;98:E336–E345.
- Brauckhoff M, Machens A, Lorenz K, et al. Surgical curability of medullary thyroid cancer in multiple endocrine neoplasia 2B. *Ann Surg* 2014;259:800–806.
- Lee R, Hyer J, Chowdhury H, et al. Ocular signs of multiple endocrine neoplasia type 2B (MEN2B). *J Clin Endocrinol Metab* 2012;97:725–726.
- Wells SA Jr, Robinson BC, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. *J Clin Oncol* 2012;30:134–141.
- Schoffski P, Elisei R, Muller S. An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline. *J Clin Oncol* 2012;30:Abstract 5508.
- Lee M, Pellegata NS. Multiple endocrine neoplasia type 4. *Horm Res* 2013;41:63–78.